Tan Li
Fondatore presso SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Patrimonio netto: 487 M $ in data 30/06/2024
Posizioni attive di Tan Li
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Direttore/Membro del Consiglio | 21/04/1998 | - |
| Fondatore | 21/04/1998 | - | |
| Corporate Officer/Principal | 21/04/1998 | - | |
| Urumqi Jintiantu Equity Investment Partnership LP | Corporate Officer/Principal | 09/08/2013 | - |
| Direttore/Membro del Consiglio | 09/08/2013 | - | |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | Direttore/Membro del Consiglio | - | - |
Shenzhen Duopule Industrial Development Co., Ltd.
 Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Direttore/Membro del Consiglio | 13/01/2014 | - |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | - | - |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Direttore/Membro del Consiglio | 20/01/2017 | - |
Storia della carriera di Tan Li
Formazione di Tan Li
| Sichuan University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Cina | 6 |
| Regno Unito | 3 |
Posizioni
| Director/Board Member | 6 |
| Corporate Officer/Principal | 2 |
| Founder | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
| Distribution Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Health Technology |
| Aziende private | 5 |
|---|---|
| Urumqi Jintiantu Equity Investment Partnership LP | |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Distribution Services |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
- Borsa valori
- Insiders
- Tan Li
- Esperienza
